Breast cancer—epidemiology, risk factors, classification, prognostic markers, and current treatment strategies—an updated review
Simple Summary Breast cancer is the most common cancer among women. It is estimated
that 2.3 million new cases of BC are diagnosed globally each year. Based on mRNA gene …
that 2.3 million new cases of BC are diagnosed globally each year. Based on mRNA gene …
Treatment landscape of triple-negative breast cancer—expanded options, evolving needs
Tumour heterogeneity and a long-standing paucity of effective therapies other than
chemotherapy have contributed to triple-negative breast cancer (TNBC) being the subtype …
chemotherapy have contributed to triple-negative breast cancer (TNBC) being the subtype …
Recent advances in therapeutic strategies for triple-negative breast cancer
Y Li, H Zhang, Y Merkher, L Chen, N Liu… - Journal of hematology & …, 2022 - Springer
Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer (BC)
with a poor prognosis. Current treatment options are limited to surgery, adjuvant …
with a poor prognosis. Current treatment options are limited to surgery, adjuvant …
Triple-negative breast cancer molecular subty** and treatment progress
L Yin, JJ Duan, XW Bian, S Yu - Breast Cancer Research, 2020 - Springer
Triple-negative breast cancer (TNBC), a specific subtype of breast cancer that does not
express estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth …
express estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth …
Deciphering breast cancer: from biology to the clinic
Breast cancer remains a leading cause of cancer-related mortality in women, reflecting
profound disease heterogeneity, metastasis, and therapeutic resistance. Over the last …
profound disease heterogeneity, metastasis, and therapeutic resistance. Over the last …
[HTML][HTML] Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy
F Yang, Y **ao, JH Ding, X **, D Ma, DQ Li, JX Shi… - Cell metabolism, 2023 - cell.com
Treatment of triple-negative breast cancer (TNBC) remains challenging. Deciphering the
orchestration of metabolic pathways in regulating ferroptosis will provide new insights into …
orchestration of metabolic pathways in regulating ferroptosis will provide new insights into …
[HTML][HTML] UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses
DS Chandrashekar, B Bashel, SAH Balasubramanya… - Neoplasia, 2017 - Elsevier
Abstract Genomics data from The Cancer Genome Atlas (TCGA) project has led to the
comprehensive molecular characterization of multiple cancer types. The large sample …
comprehensive molecular characterization of multiple cancer types. The large sample …
Pathogenesis of triple-negative breast cancer
F Derakhshan, JS Reis-Filho - Annual Review of Pathology …, 2022 - annualreviews.org
Triple-negative breast cancer (TNBC) encompasses a heterogeneous group of
fundamentally different diseases with different histologic, genomic, and immunologic …
fundamentally different diseases with different histologic, genomic, and immunologic …
PI3K/AKT/mTOR signaling pathway in breast cancer: from molecular landscape to clinical aspects
Breast cancer is a serious health problem worldwide, representing the second cause of
death through malignancies among women in developed countries. Population …
death through malignancies among women in developed countries. Population …
Triple negative breast cancer: Pitfalls and progress
P Zagami, LA Carey - NPJ breast cancer, 2022 - nature.com
Triple negative breast cancer (TNBC) is characterized by the lack of estrogen and
progesterone receptor expression and lacks HER2 overexpression or gene amplification. It …
progesterone receptor expression and lacks HER2 overexpression or gene amplification. It …